Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 6 of 382 rows for Antihypertensives / BP lowering. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Antihypertensives / BP lowering Medicines | Prevention |
Mixed
whyAntihypertensive treatment improved cognitive scores by a small amount (SMD 0.06, moderate certainty) but the reduction in dementia incidence was not statistically significant (OR 0.89, low certainty). The drug-class rankings rest on one trial per class and are described as highly uncertain. |
Cognitive function scores and incident dementia in hypertensive older adults (four RCTs) | meta-analysis | 16,823 | Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P < .001, GRADE moderate certainty) and showed a nonsignificant trend toward reduced dementia incidence (OR, 0.89; 95% CI, 0.76-1.05; P = .172, GRADE low certainty) |
Journal of the American Medical Directors Association
2026 ✓ Peer-reviewed PMID 41962914 |
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whySignificant for MCI and for the MCI-or-dementia composite; not significant for probable dementia alone (HR 0.86, 95% CI 0.72-1.02). |
MCI and probable dementia over median 7 years | randomised trial | 9,361 | Probable dementia: 8.5 vs. 10.2 per 1,000 person-years (HR 0.86, 95% CI 0.72-1.02); MCI: HR 0.87 (95% CI 0.76-1.00); composite MCI-or-dementia: HR 0.89 (95% CI 0.79-0.99) |
Neurology
2025 ✓ Peer-reviewed PMID 39819096 |
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whyA large drop in blood pressure (22/9 mmHg) and fewer serious adverse events in the intervention villages. |
All-cause dementia over 48 months | randomised trial | 33,995 | All-cause dementia RR 0.85 (95% CI 0.76-0.95) |
Nature Medicine
2025 ✓ Peer-reviewed PMID 40258956 |
| Antihypertensives / BP lowering Medicines | Prevention |
Mixed
whyAntihypertensive use tracked lower Alzheimer's risk but not lower non-Alzheimer dementia risk, where treated and untreated hypertension looked the same. A single baseline blood pressure reading predicted neither. |
Alzheimer's and non-Alzheimer dementia | meta-analysis | 31,250 | Untreated vs treated hypertension: Alzheimer's dementia HR 1.42 (95% CI 1.08-1.87) |
Neurology
2024 ✓ Peer-reviewed PMID 39141884 |
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whyIndividual participant data from five double-blind placebo-controlled trials, which is the strongest design in this table for this exposure. |
Incident dementia over a median 4.3 years | meta-analysis | 28,008 | Adjusted OR 0.87 (95% CI 0.75-0.99) for incident dementia |
European Heart Journal
2022 ✓ Peer-reviewed PMID 36282295 |
| Antihypertensives / BP lowering Medicines | Prevention |
Benefit
whyConsistent across 14 trials (I-squared 0%) but small in absolute terms: 0.39 percentage points over about 4 years. |
Incident dementia or cognitive impairment | meta-analysis | 96,158 | OR 0.93 (95% CI 0.88-0.98); absolute risk reduction 0.39% over 4.1 years |
JAMA
2020 ✓ Peer-reviewed PMID 32427305 |
Last updated